Clinical trials: Respiratory Distress Syndrome (RDS)
Acute Respiratory Distress Syndrome
Efficacy and Safety of Anakinra in Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition characterized by acute respiratory failure with hypoxemia, noncardiogenic or non-fluid overload pulmonary edema, bilateral diffuse opacities on chest…
- Trial name
- ESKA (NCT05914454)
- Testing
- Anakinra 100Mg/0.67Ml Inj Syringe
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Azienda Sanitaria-Universitaria Integrata di Udine
Respiratory Distress Syndrome
Non Inferiority Trial Investigating Surfactants Administered Via MIST
RESEARCH DESIGN Multicenter, randomized, controlled trial. RECRUITMENT Entry criteria Preterm infants 28-35 6/7 weeks' gestation and less than 48 hours of age who have a clinical diagnosis of respiratory distress syndrome.
- Trial name
- Niftisurf (NCT06074380)
- Testing
- MIST surfactant
- Where
- United States
- Volunteers
- 262 people
- Sponsor
- Endeavor Health
RDS of Prematurity, Surfactant Protein B Deficiency
Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot Study
A pilot study to explore and determine feasibility and safety of the administration of surfactant through a new supraglottic device in patients from 500 to 5000 grams with RDS.
- Conditions
- RDS of Prematurity, Surfactant Protein B Deficiency, Chronic Lung Disease
- Trial name
- NCT04056741
- Testing
- surfactant airway device
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- ONY
Acute Respiratory Distress Syndrome
Effects of End-inspiratory Pause on Ventilation
This study aims to evaluate the effect of reducing tidal volume and respiratory rate together with an end-inspiratory pause setting on ventilatory efficiency and the distribution of inspired gas within the lungs in ARDS patients.
- Trial name
- NCT06692634
- Testing
- mechanical ventilation setting
- Where
- 2 sites in Chile
- Volunteers
- 20 people
- Sponsor
- Clinica las Condes, Chile
Acute Respiratory Distress Syndrome
Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) is a serious condition where people in hospital care suddenly have trouble breathing because of infection, pneumonia, COVID-19 or other disease.
- Trial name
- NCT06640777
- Testing
- LEAF-4L6715, Supportive Care
- Where
- France
- Volunteers
- 310 people
- Sponsor
- LEAF4Life, Inc.
Transient Tachypnea of the Newborn, Neonatal Respiratory Distress
Efficacy of Misoprostol in Prevention of Neonatal Respiratory Morbidity in Parturient at Early Term Elective Caesarian Section
Neonatal respiratory morbidities represent a common group of post natal complications including respiratory distress syndrome, transient tachypnea of newborn, and persistent pulmonary hypertension of newborn.
- Trial name
- NCT04780412
- Testing
- Misoprostol
- Where
- Egypt
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary…
- Conditions
- Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia
- Trial name
- NCT00029328
- Testing
- etanercept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- FDA Office of Orphan Products Development
Acute Lung Injury
The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury
This is a double-blind, placebo-controled, randomized trial to investigate if aspirin pre-treatment has anti-inflammatory effects in a model of acute lung injury induced by inhaled endotoxin (LPS) in healthy human volunteers.
- Trial name
- ARENA (NCT01659307)
- Testing
- Aspirin 75mg, Lactose powder, Aspirin 1200mg
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Belfast Health and Social Care Trust
Acute Respiratory Distress Syndrome
Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)
At the beginning COVID-associated lung injury was considered as typical ARDS, hence respiratory and nonrespiratory treatments were delivered according to general principles for this kind of illness.
- Trial name
- AtTAC (NCT04453371)
- Testing
- Tissue plasminogen activator, Ringer solution
- Sponsor
- Negovsky Reanimatology Research Institute
Acute Respiratory Distress Syndrome, Cardiogenic Shock
Study of Immunity Dysfunction Induced by Extracorporeal Assistance (ECMO / ECLS)
Study of immunosuppression biomarkers in patients with ARDS or cardiogenic shock with ECMO / ECLS, compared to patients with ARDS or cardiogenic shock without ECMO / ECLS
- Trial name
- IMPEC (NCT03262155)
- Testing
- Blood test
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Rennes University Hospital
Fiberoptic Bronchoscopy (FOB), Bronchoalveolar Lavage (BAL)
Fiberoptic Bronchoscopy and Bronchoalveolar Lavage in Critically Ill Ventilated Patients
Fiberoptic bronchoscopy (FOB) is widely used as a diagnostic or therapeutic procedure in intensive care units. Patients with ARDS or COVID-19 disease often undergoes to these procedures.
- Conditions
- Fiberoptic Bronchoscopy (FOB), Bronchoalveolar Lavage (BAL), Respiratory Disease
- Trial name
- NCT04502368
- Testing
- Fiberoptic Bronchoscopy (FOB), Bronchoalveolar Lavage (BAL), Electrical Impedance Tomography (EIT)
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- Erasme University Hospital
Acute Respiratory Distress Syndrome, Lung Diseases
Ibuprofen in Sepsis Study
To determine the effects of ibuprofen on mortality, development and reversal of shock, and adult respiratory distress syndrome, and on Lung Parenchymal Injury Score in adult patients with serious infection.
- Conditions
- Acute Respiratory Distress Syndrome, Lung Diseases, Shock, Septic
- Trial name
- NCT00000574
- Testing
- ibuprofen
- Sponsor
- Vanderbilt University
Survival, Prosthesis, Oxygen Deficiency
Awake Prone Positioning for COVID-19 Acute Hypoxaemic Respiratory Failure
The objective of our study is to evaluate the effectiveness of prone position in preventing intubation or death in spontaneously ventilated patients with COVID-19 with acute respiratory failure.
- Trial name
- NCT05866289
- Testing
- Prone position
- Where
- Morocco
- Volunteers
- 1,069 people, healthy volunteers welcome
- Sponsor
- Mohammed VI University Hospital
Transient Tachypnea of Newborn
Comparison of Nasal CPAP and Nasal SIMV in Transient Tachypnea of Newborn
The investigators aimed to compare the efficacy of nasal SIMV and nasal CPAP in patients with wet lung.
- Trial name
- NCT01499238
- Testing
- Nasal SIMV, nasal CPAP
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital
ARDS, Human, COVID-19
London's Exogenous Surfactant Study for COVID19
The research team is investigating administering exogenous surfactant in COVID-19 patients with ARDS. The overall goal is to improve the outcome (mortality) of mechanically ventilated COVID-19 patients.
- Trial name
- LESSCOVID (NCT04375735)
- Testing
- Bovine Lipid Extract Surfactant
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Acute Respiratory Distress Syndrome
Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)
The primary object of this clinical study is to investigate the efficacy and the safety of NOA-001 in patients with ARDS (ARDS caused by Non-COVID-19 or COVID-19).
- Trial name
- NCT04804943
- Testing
- NOA-001
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Toray Industries, Inc
Neonatal Respiratory Distress, Oxygenation
Neonatal Oximeter Bias Study
The study aims to determine if there is a systematic difference (bias) between pulse oximeters used in control systems for automated oxygen delivery (A-FiO2) and those used in monitoring systems.
- Trial name
- NOB (NCT06817850)
- Where
- Czechia
- Volunteers
- 40 people
- Sponsor
- Czech Technical University in Prague
Respiratory Distress Syndrome, Newborn, Premature Birth
SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required…
- Conditions
- Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
- Trial name
- NCT00215540
- Testing
- Lucinactant 175 mg/kg, Lucinactant 90 mg/kg
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Windtree Therapeutics
ARDS (Acute Respiratory Distress Syndrome), VILI (Ventilator-induced Lung Injury)
Real-Time Algorithm-Driven Ventilation Feedback to Improve Lung-Protective Ventilation in Patients With ARDS (REALVENT-study)
The REALVENT trial is designed to evaluate whether a real-time, algorithm-driven ventilation feedback strategy can improve lung-protective ventilation (LPV) achievement rates in critically ill patients receiving invasive…
- Conditions
- ARDS (Acute Respiratory Distress Syndrome), VILI (Ventilator-induced Lung Injury), Respiratory Failure, Critical Illness
- Trial name
- REALVENT (NCT07307066)
- Testing
- REal-time Algorithm-driven Ventilation feedback to improve lung-protective ventilation in critically, Standard ICU care
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Peking Union Medical College Hospital
Acute Respiratory Distress Syndrome, Pneumonia
Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia
This study will investigate the safety and efficacy of the administration of inhaled GM-CSF to patients with respiratory virus-associated pneumonia.
- Conditions
- Acute Respiratory Distress Syndrome, Pneumonia, Respiratory Virus Infection
- Trial name
- iGRASP (NCT02601365)
- Testing
- Sargramostim 0.04 mcg/kg/dose, Sargramostim 0.2mcg/kg/dose, Sargramostim 1 mcg/kg/dose
- Sponsor
- Milton S. Hershey Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.